ES2983492T3 - Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos - Google Patents
Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos Download PDFInfo
- Publication number
- ES2983492T3 ES2983492T3 ES17757849T ES17757849T ES2983492T3 ES 2983492 T3 ES2983492 T3 ES 2983492T3 ES 17757849 T ES17757849 T ES 17757849T ES 17757849 T ES17757849 T ES 17757849T ES 2983492 T3 ES2983492 T3 ES 2983492T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- group
- antigen
- binding portion
- psma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614162.4A GB201614162D0 (en) | 2016-08-18 | 2016-08-18 | Antibodies, uses thereof and conjugates thereof |
| PCT/GB2017/052448 WO2018033749A1 (en) | 2016-08-18 | 2017-08-18 | Anti-psma antibodies, uses thereof and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2983492T3 true ES2983492T3 (es) | 2024-10-23 |
Family
ID=57045541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17757849T Active ES2983492T3 (es) | 2016-08-18 | 2017-08-18 | Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11059903B2 (enExample) |
| EP (2) | EP4403226A3 (enExample) |
| JP (2) | JP7039554B2 (enExample) |
| CN (1) | CN110049999B (enExample) |
| ES (1) | ES2983492T3 (enExample) |
| GB (1) | GB201614162D0 (enExample) |
| WO (1) | WO2018033749A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| SG11202009670RA (en) * | 2018-03-29 | 2020-10-29 | Ambrx Inc | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
| EP3994177A4 (en) * | 2019-07-02 | 2023-09-20 | Telix International Pty Ltd | PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR |
| CN114729059A (zh) | 2019-09-11 | 2022-07-08 | 宾夕法尼亚大学董事会 | 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法 |
| CN113677704B (zh) * | 2019-11-22 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | Psma抗体及其应用 |
| CN110922486B (zh) * | 2020-02-18 | 2020-05-22 | 和铂医药(上海)有限责任公司 | 一种分离的结合抗原psma的蛋白及其用途 |
| IL322523A (en) * | 2023-02-28 | 2025-10-01 | Eisai R&D Man Co Ltd | Anti-PSMA antibodies, conjugates and methods of use |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| CN116271081A (zh) * | 2023-04-04 | 2023-06-23 | 上海愿智生物技术有限公司 | 一种抗体偶联药物yc1605及其药物组合物和应用 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| WO2026044149A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| CN1294588C (zh) | 1996-07-24 | 2007-01-10 | 皇家菲利浦电子有限公司 | 光盘录取装置 |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
| US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2386366T3 (es) | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
| CA2598454C (en) * | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US9364557B2 (en) | 2007-08-01 | 2016-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fold-back diabody diphtheria toxin immunotoxin and methods of use |
| US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
| CN101891818B (zh) * | 2009-01-16 | 2012-07-25 | 中国人民解放军第四军医大学 | 抗人前列腺特异性膜抗原胞外区单链抗体及其应用 |
| US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
| BR112014031613A2 (pt) * | 2012-06-19 | 2017-07-25 | Polytherics Ltd | processo para preparação de conjugados de anticorpos e conjugados de anticorpos |
| NO2789793T3 (enExample) | 2012-10-24 | 2018-01-27 | ||
| ES2623209T3 (es) | 2012-10-24 | 2017-07-10 | Polytherics Limited | Conjugados fármaco-proteína |
| AU2014386824B2 (en) * | 2013-03-15 | 2019-05-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2015057250A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| JP6908964B2 (ja) | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| DK3151865T3 (da) * | 2014-05-22 | 2021-10-25 | Byondis Bv | Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
-
2016
- 2016-08-18 GB GBGB1614162.4A patent/GB201614162D0/en not_active Ceased
-
2017
- 2017-08-18 WO PCT/GB2017/052448 patent/WO2018033749A1/en not_active Ceased
- 2017-08-18 CN CN201780044227.8A patent/CN110049999B/zh active Active
- 2017-08-18 EP EP24173428.4A patent/EP4403226A3/en active Pending
- 2017-08-18 US US16/303,600 patent/US11059903B2/en active Active
- 2017-08-18 ES ES17757849T patent/ES2983492T3/es active Active
- 2017-08-18 JP JP2019502698A patent/JP7039554B2/ja active Active
- 2017-08-18 EP EP17757849.9A patent/EP3500595B1/en active Active
-
2022
- 2022-03-08 JP JP2022035222A patent/JP7486538B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3500595A1 (en) | 2019-06-26 |
| JP2019535232A (ja) | 2019-12-12 |
| GB201614162D0 (en) | 2016-10-05 |
| JP7486538B2 (ja) | 2024-05-17 |
| US11059903B2 (en) | 2021-07-13 |
| EP4403226A2 (en) | 2024-07-24 |
| EP3500595B1 (en) | 2024-05-01 |
| WO2018033749A1 (en) | 2018-02-22 |
| CN110049999B (zh) | 2023-12-19 |
| JP2022084715A (ja) | 2022-06-07 |
| US20190300623A1 (en) | 2019-10-03 |
| EP4403226A3 (en) | 2024-10-16 |
| JP7039554B2 (ja) | 2022-03-22 |
| CN110049999A (zh) | 2019-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7486538B2 (ja) | 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート | |
| JP7564176B2 (ja) | 抗体、その使用及びそのコンジュゲート | |
| JP7016975B2 (ja) | ナノ粒子イムノコンジュゲート | |
| ES2769538T3 (es) | Kit de predireccionamiento, método y agentes que se usan en éste | |
| ES2874493T3 (es) | Sitios específicos para modificar anticuerpos para generar inmunoconjugados | |
| CN106995493B (zh) | 氯毒素多肽和结合物及其应用 | |
| US20190375837A1 (en) | Immunocytokine combination therapy | |
| ES2747727T3 (es) | Composiciones y métodos para el diagnóstico y tratamiento del cáncer | |
| US20180078654A1 (en) | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens | |
| ES2913401T3 (es) | Nuevo fragmento Fab de anticuerpo anti-MUC1 humana | |
| KR20220015504A (ko) | 단백질-폴리머-약물 접합체 | |
| KR20200051802A (ko) | 항-엽산 수용체 알파 항체 접합체 및 이의 용도 | |
| ES2625829T3 (es) | Conjugados y sus usos en la obtención de imágenes moleculares | |
| WO2025209500A1 (zh) | Nectin-4单域抗体及其用途 | |
| TW201708407A (zh) | 螢光綴合物 | |
| EP4612189A1 (en) | Radionuclide and near-infrared dye conjugated antibody for detection of gd2-positive cancer | |
| CN121866076A (zh) | 新型治疗靶标 | |
| Guley | Serum Albumin as a Carrier of Immunostimulatory Oligodeoxynucleotides for Cancer Therapy | |
| BR112017020689B1 (pt) | Imunoconjugado comprendendo uma nanopartícula revestida com um políomero orgânico e um fragmento de anticorpo conjugado à mesma |